Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Editas Medicine (EDIT) shares have risen approximately 40% since its last earnings report, outperforming the S&P 500, despite downward trending earnings estimates. While Editas has a strong Momentum Score of A, its Value Score is an F and it holds a Zacks Rank #3 (Hold), suggesting an expected in-line return in the near term. Mirum Pharmaceuticals (MIRM), a peer in the same industry, has also seen gains of 8.2% over the past month, with a VGM Score of B and a Zacks Rank #3 (Hold).

Analysis

Editas Medicine (EDIT) has experienced a significant share price appreciation of approximately 40% since its last earnings report, notably outperforming the S&P 500. This rally, however, contrasts with a downward trend in earnings estimate revisions for the company over the past month, although the net magnitude of these revisions has been zero. Editas exhibits a strong Momentum Score of A, but its Growth Score is average at C, and its Value Score is notably poor at F, placing it in the bottom quintile for value-oriented investment strategies. Consequently, its aggregate VGM Score is D. The company currently holds a Zacks Rank #3 (Hold), indicating expectations for an in-line return relative to the market in the coming months. In comparison, Mirum Pharmaceuticals (MIRM), a peer in the Zacks Medical - Biomedical and Genetics industry, has gained 8.2% over the past month. Mirum reported a 61.2% year-over-year increase in revenues to $111.58 million in its last reported quarter (ended March 2025) and an improved EPS of -$0.30 compared to -$0.54 a year ago. Mirum is projected to post a loss of $0.32 per share for the current quarter, a 38.5% year-over-year improvement, and its Zacks Consensus Estimate has risen by 3.8% over the last 30 days, contributing to its Zacks Rank #3 (Hold) and a more favorable VGM Score of B.

Key Decisions for Investors

• Investors should exercise caution regarding Editas Medicine's recent 40% share price surge, as it is accompanied by declining earnings estimate trends and a weak 'F' Value Score, despite strong 'A' Momentum.
• Given Editas's Zacks Rank #3 (Hold) and overall 'D' VGM score, a wait-and-see approach may be warranted, focusing on the next earnings release for signs of fundamental improvement before committing new capital.
• Consider the contrasting profile of industry peer Mirum Pharmaceuticals, which, while also a 'Hold,' shows recent revenue growth and improving EPS, potentially offering a different risk-reward balance within the biotech sector.